Phase 3 diabetes evidence
Two peer-reviewed Phase 3 studies reported improvements in blood-sugar control and body weight across different groups of adults with type 2 diabetes.
P—03 • Triple-receptor development profile
Retatrutide
An investigational triple-receptor peptide with an expanding Phase 3 evidence base across obesity, type 2 diabetes, and related metabolic complications.
Name
Retatrutide
Also known as LY3437943
- Scientific classification
- Single-peptide GIP, GLP-1, and glucagon receptor agonist
- Library family
- Metabolic
- Regulatory status
- Investigational and not FDA approved
Compound overview
A triple-receptor peptide moving through a broad late-stage research program.
Retatrutide is a synthetic investigational peptide designed to activate the receptors for GIP, GLP-1, and glucagon within a single molecule. Researchers are studying whether this coordinated signaling can influence appetite, blood-sugar control, nutrient handling, and energy use in complementary ways.
Early clinical studies produced encouraging metabolic findings and led to an extensive Phase 3 program. That program now includes research involving obesity, type 2 diabetes, cardiovascular disease, chronic kidney disease, knee osteoarthritis, and obstructive sleep apnea.
Peer-reviewed Phase 3 findings published in 2026 strengthened the evidence base. TRANSCEND-T2D-1 reported improvements in blood-sugar control and body weight in adults with type 2 diabetes managed with diet and exercise, while TRIUMPH-2 reported significant body-weight and blood-sugar improvements in adults with obesity or overweight and type 2 diabetes.
Additional Phase 3 announcements have reported positive weight-management findings in people with obesity, including groups with cardiovascular disease or knee osteoarthritis. The TRIUMPH-4 study also reported improvements in knee-pain and physical-function measures, creating interest in how metabolic change may affect daily mobility.
Retatrutide remains investigational. Longer-term heart and kidney outcomes, direct comparisons with other metabolic medicines, durability, tolerability, and regulatory review are still important parts of the story.
Obesity and daily function
The broader TRIUMPH program is examining weight management alongside complications such as knee osteoarthritis, sleep apnea, and cardiovascular disease.
Long-term outcomes
A large ongoing outcomes trial is testing whether retatrutide can reduce major heart and kidney events, while a head-to-head study is comparing it with tirzepatide.
Mechanism under study
Coordinated triple-receptor signaling
Retatrutide combines activity at three metabolically relevant receptors within one peptide. Researchers are studying how their combined signaling influences appetite, glucose regulation, nutrient handling, and energy balance.
GIP receptor
Participates in glucose-dependent insulin signaling and nutrient-response pathways.
GLP-1 receptor
Influences appetite, glucose-dependent insulin release, and gastrointestinal signaling.
Glucagon receptor
Participates in hepatic energy metabolism and pathways related to energy expenditure.
The contribution of each receptor—and the long-term effect of their combined activation—remains an active area of research.
Current research areas
Questions under investigation
- Blood-sugar control and long-term weight management
- Heart and kidney outcomes
- Knee pain, mobility, and everyday physical function
- Sleep apnea and other complications linked with obesity
- Long-term safety and comparisons with other metabolic medicines
Evidence summary
Promising late-stage clinical findings
- Body-weight outcomes: Phase 2 and Phase 3 studies have reported substantial average body-weight reductions, with results differing by dose, study population, duration, and analysis method.
- Blood-sugar control: Peer-reviewed Phase 3 trials in adults with type 2 diabetes reported reductions in HbA1c alongside body-weight changes.
- Cardiometabolic markers: Recent research has reported favorable changes in several lipid and cardiovascular-risk biomarkers. Whether those changes translate into fewer major cardiovascular events is still being tested.
- Knee osteoarthritis: TRIUMPH-4 topline findings reported improvements in knee-pain and physical-function measures among studied adults with obesity or overweight and knee osteoarthritis.
- Broader outcomes: Ongoing studies are examining heart, kidney, sleep-apnea, and long-term health outcomes rather than relying only on changes in body weight.
Retatrutide remains investigational. Results come from defined clinical-trial populations and do not establish an approved use or guarantee individual outcomes.
Educational notice
Education, not usage guidance.
This profile is provided for scientific education only. It is not medical advice, a treatment recommendation, dosing information, or instructions for use. Retatrutide is investigational and is not approved by the FDA.
Key scientific referencesComing soon
A curated primary-source reference list will be added during the next educational expansion.